A detailed history of Rhumbline Advisers transactions in Macrogenics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 88,294 shares of MGNX stock, worth $369,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares
88,294
Previous 93,099 5.16%
Holding current value
$369,951
Previous $1.37 Million 72.63%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$3.31 - $18.51 $15,904 - $88,940
-4,805 Reduced 5.16%
88,294 $375,000
Q1 2024

May 09, 2024

BUY
$9.77 - $21.47 $25,890 - $56,895
2,650 Added 2.93%
93,099 $1.37 Million
Q4 2023

Feb 08, 2024

SELL
$4.48 - $10.11 $1,008 - $2,274
-225 Reduced 0.25%
90,449 $870,000
Q3 2023

Nov 09, 2023

BUY
$4.48 - $6.19 $1,594 - $2,203
356 Added 0.39%
90,674 $422,000
Q2 2023

Aug 08, 2023

SELL
$4.62 - $7.54 $23,552 - $38,438
-5,098 Reduced 5.34%
90,318 $483,000
Q1 2023

May 11, 2023

BUY
$4.82 - $7.24 $8,584 - $12,894
1,781 Added 1.9%
95,416 $684,000
Q4 2022

Feb 14, 2023

BUY
$3.34 - $6.98 $2,648 - $5,535
793 Added 0.85%
93,635 $628,000
Q3 2022

Nov 10, 2022

BUY
$3.01 - $5.22 $15,215 - $26,387
5,055 Added 5.76%
92,842 $321,000
Q2 2022

Aug 11, 2022

BUY
$2.25 - $9.99 $54,454 - $241,777
24,202 Added 38.06%
87,787 $259,000
Q1 2022

May 12, 2022

SELL
$8.12 - $16.9 $4,652 - $9,683
-573 Reduced 0.89%
63,585 $560,000
Q4 2021

Feb 10, 2022

SELL
$15.91 - $21.88 $7,127 - $9,802
-448 Reduced 0.69%
64,158 $1.03 Million
Q3 2021

Nov 12, 2021

BUY
$19.74 - $28.7 $53,653 - $78,006
2,718 Added 4.39%
64,606 $1.35 Million
Q2 2021

Aug 05, 2021

SELL
$20.49 - $35.63 $346,362 - $602,289
-16,904 Reduced 21.45%
61,888 $1.66 Million
Q1 2021

May 06, 2021

SELL
$18.99 - $33.2 $106,951 - $186,982
-5,632 Reduced 6.67%
78,792 $2.51 Million
Q4 2020

Feb 10, 2021

BUY
$19.41 - $26.0 $208,288 - $279,006
10,731 Added 14.56%
84,424 $1.93 Million
Q3 2020

Nov 12, 2020

SELL
$24.69 - $31.6 $219,197 - $280,544
-8,878 Reduced 10.75%
73,693 $1.86 Million
Q2 2020

Aug 13, 2020

BUY
$5.2 - $29.12 $49,998 - $279,988
9,615 Added 13.18%
82,571 $2.31 Million
Q1 2020

May 06, 2020

BUY
$4.28 - $12.11 $15,279 - $43,232
3,570 Added 5.15%
72,956 $425,000
Q4 2019

Feb 05, 2020

BUY
$7.95 - $12.27 $8,776 - $13,546
1,104 Added 1.62%
69,386 $755,000
Q3 2019

Oct 23, 2019

BUY
$12.44 - $17.48 $49,834 - $70,024
4,006 Added 6.23%
68,282 $871,000
Q2 2019

Aug 14, 2019

BUY
$14.51 - $19.71 $192,489 - $261,472
13,266 Added 26.01%
64,276 $1.09 Million
Q1 2019

May 01, 2019

SELL
$11.11 - $25.6 $7,277 - $16,768
-655 Reduced 1.27%
51,010 $917,000
Q4 2018

Jan 31, 2019

BUY
$11.75 - $21.42 $199,162 - $363,069
16,950 Added 48.83%
51,665 $656,000
Q3 2018

Nov 07, 2018

SELL
$19.26 - $23.46 $46,301 - $56,397
-2,404 Reduced 6.48%
34,715 $744,000
Q2 2018

Aug 06, 2018

BUY
$19.78 - $24.67 $75,243 - $93,844
3,804 Added 11.42%
37,119 $767,000
Q1 2018

May 02, 2018

SELL
$18.89 - $32.46 $16,717 - $28,727
-885 Reduced 2.59%
33,315 $838,000
Q4 2017

Feb 09, 2018

SELL
$16.19 - $20.3 $101,997 - $127,890
-6,300 Reduced 15.56%
34,200 $650,000
Q3 2017

Nov 06, 2017

BUY
$15.52 - $18.94 $628,560 - $767,070
40,500
40,500 $748,000

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $258M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.